VetMedGuide

Vet Med Guide

Companion animal beside veterinary diagnostic materials.
Diagnostics2026-06-18 · 11 min read

Chronic Kidney Disease in Dogs: IRIS Staging, SDMA, Proteinuria, and Management

Canine CKD workup — IRIS staging by creatinine and SDMA, UPC and blood-pressure substaging, renal diet and phosphate binders, telmisartan vs benazepril, and median survival by stage.

Ran Chen
Ran Chen
Founder, VetMedGuide. Life-sciences operator and 10× global market-access lead.
Published

Chronic kidney disease (CKD) is less common in dogs than in cats, but when it occurs it is progressive, irreversible, and managed rather than cured — so the workup is built around staging the patient accurately and then matching the treatment to the stage. The framework veterinarians use is the IRIS (International Renal Interest Society) staging system, which places a dog into one of four stages by kidney function and then sub-stages it by proteinuria and blood pressure. That staging is not academic: it predicts survival, and it tells the team which interventions — renal diet, phosphate binders, anti-proteinuric drugs, blood-pressure medication — will actually help at each stage.

This article is the canine CKD workup and management plan, with the IRIS numbers that drive decisions. It complements the site's feline CKD treatment page (the species differ in important ways, summarized below) and the SDMA vs creatinine lab-interpretation article. The decisions an owner and veterinarian are making together are how hard to push diagnostics, which combination of diet and drugs to start, and how honestly to set expectations — because median survival ranges from well over a year in early disease down to weeks in end-stage disease.

Quick answer

Chronic kidney disease in dogs is a gradual, irreversible loss of nephron function that shows up as persistently elevated creatinine and/or SDMA, inadequate urine concentrating ability, and — in many dogs — protein loss in the urine. It is staged by the IRIS system into Stage 1–4 using fasting creatinine and SDMA (measured on at least two occasions in a stable, hydrated dog), then sub-staged by the urine protein-to-creatinine ratio (UPC) and blood pressure. Management is built on a phosphorus-restricted renal diet (which slows progression and reduces the risk of a uremic crisis), intestinal phosphate binders when diet alone cannot control phosphorus, and anti-proteinuric therapy — with current IRIS guidance favoring an angiotensin-receptor blocker such as telmisartan over an ACE inhibitor such as benazepril for proteinuric dogs. Median survival falls sharply with stage: from more than 400 days in Stage 1, to roughly 200–400 days in Stage 2, 110–200 days in Stage 3, and 14–80 days in Stage 4. The earlier the disease is caught and the tighter the control of phosphorus, proteinuria, and blood pressure, the longer and better the dog's remaining life.

How canine CKD differs from the feline disease, and what causes it

Two features distinguish canine CKD from the feline version that most owners have heard about. First, glomerular disease and protein-losing kidney injury are relatively more important in dogs — many dogs with CKD have significant proteinuria, which both reflects glomerular damage and accelerates it, making the UPC a central (not optional) part of the workup. Second, concurrent endocrine disease drives a lot of canine CKD: dogs with Cushing's disease or diabetes mellitus develop hypertension and proteinuria that damage the kidneys over time, and CKD is often discovered while working up one of those.

Underlying causes and contributors include chronic interstitial nephritis (often idiopathic, the end-stage of prior injury), glomerulonephritis and amyloidosis (glomerular disease, prominent in certain breeds), chronic pyelonephritis, congenital and familial disease (for example, renal dysplasia in some breeds, hereditary glomerular disease), and prior acute injury that did not fully recover — including leptospirosis, toxin exposure (notably NSAID-related kidney injury, relevant to long-term NSAID use), and episodes that left scarred, non-functioning tissue. By the time CKD is diagnosed, the original cause is often no longer identifiable or treatable, so management focuses on slowing further loss rather than reversing damage.

Typical presentation: middle-aged to older dogs, with signs that include increased thirst and urination, weight loss, decreased appetite, vomiting, lethargy, and occasionally mouth ulcers or bad breath in advanced disease. Because these signs are nonspecific and overlap with many other diseases, CKD is confirmed and quantified with lab work, not symptoms alone.

Diagnosis and the IRIS staging numbers

CKD is diagnosed by combining persistent changes in kidney markers with inadequate urine concentrating ability, in a stable patient, after ruling out non-renal causes and acute (potentially reversible) kidney injury. Staging is then done with fasting blood creatinine and/or SDMA, ideally both, on at least two occasions in a hydrated, stable dog. The IRIS canine staging values are:

  • Stage 1 (non-azotemic): creatinine < 1.4 mg/dL; SDMA < 18 µg/dL. The dog has some renal abnormality (low urine specific gravity, abnormal kidneys on palpation or imaging, renal proteinuria) but creatinine is still in the normal range.
  • Stage 2 (mild azotemia): creatinine 1.4–2.8 mg/dL; SDMA 18–35 µg/dL. Often clinically silent.
  • Stage 3 (moderate azotemia): creatinine 2.9–5.0 mg/dL; SDMA 36–54 µg/dL. Extrarenal signs begin to appear.
  • Stage 4 (severe azotemia): creatinine > 5.0 mg/dL; SDMA > 54 µg/dL. High risk of a uremic crisis.

A persistent SDMA above the upper reference limit of 14 µg/dL supports a diagnosis of CKD even when creatinine is normal, because SDMA can detect a fall in glomerular filtration of roughly 25% — earlier than creatinine, which only rises after substantial function is lost. When creatinine and SDMA disagree — for example, an SDMA persistently above 35 µg/dL with creatinine still in the Stage 2 band — IRIS advises assigning the higher stage and treating accordingly. Two cautions are worth stating: creatinine depends on muscle mass, so a thin, cachexic dog can have a deceptively low value, and SDMA can be elevated by non-renal disease (notably lymphoma) — so a single number is never staged in isolation; the trend across two or more visits, with the same lab, is what matters.

Substaging: proteinuria and blood pressure

After the stage, the dog is sub-staged on two axes that independently worsen prognosis and change treatment. Proteinuria is quantified by the urine protein-to-creatinine ratio (UPC): in dogs, a UPC < 0.2 is non-proteinuric, 0.2–0.5 is borderline, and > 0.5 is proteinuric (the threshold for treatment). Because proteinuria of renal origin both reflects glomerular injury and accelerates progressive kidney damage, identifying and treating it is one of the highest-yield interventions in canine CKD — more so than in cats, where the UPC is often less central.

Blood pressure is the second axis, because hypertension both results from CKD and damages the kidneys, eyes, heart, and brain. IRIS classifies systolic blood pressure as normotensive (< 140 mm Hg), prehypertensive (140–159), hypertensive (160–179), and severely hypertensive (≥ 180), with the classification ideally based on multiple readings over repeated visits in an acclimated dog. The substage combination — for example, "IRIS Stage 3, proteinuric, hypertensive" — then drives which drugs are added.

Management: diet, phosphorus, proteinuria, and blood pressure

A renal therapeutic diet is the cornerstone and the best-evidenced single intervention. Randomized, controlled studies show that a phosphorus- and protein-restricted renal diet slows progression, maintains or improves body condition, and — in a landmark canine study — reduced the risk of a uremic crisis by roughly 72% relative to a maintenance diet, while prolonging survival and quality of life. Diets such as Hill's k/d, Royal Canin Renal Support, and Purina NF are the common options; the transition should be gradual over a week or two to avoid food aversion.

Phosphorus control is the next priority, because hyperphosphatemia drives secondary hyperparathyroidism, renal osteodystrophy, and is independently associated with mortality. Target serum phosphorus is roughly < 4.5 mg/dL in Stage 2, < 5 mg/dL in Stage 3, and < 6 mg/dL in Stage 4. When diet alone cannot reach the target, an intestinal phosphate binder is added and given with meals: aluminum hydroxide is often first-line, lanthanum carbonate is an alternative (compounding may be needed for small dogs), and calcium-based binders are used cautiously and avoided when the dog is hypercalcemic or the calcium×phosphorus product exceeds 70.

Anti-proteinuric therapy is where IRIS guidance has shifted in recent years. For renal proteinuria with a UPC above 0.5 in azotemic CKD, current IRIS treatment recommendations favor an angiotensin-receptor blocker (ARB) such as telmisartan as first-line, ahead of an ACE inhibitor (ACEi) such as benazepril, based on randomized trial evidence — in one study telmisartan produced a greater percentage reduction in UPC than enalapril in proteinuric dogs. A realistic goal is a roughly 50% reduction in UPC from baseline to the lowest achievable without harm. ACE inhibitors remain reasonable options and are still used (benazepril reduced proteinuria in a multicenter canine trial, though without a clear overall survival benefit), but combining an ACEi and an ARB is not recommended because the additive toxicity — worsening azotemia, hyperkalemia, and gastrointestinal signs — is concerning. For the feline context, see the site's telmisartan for cats article.

Blood-pressure control uses amlodipine (a calcium-channel blocker) as the mainstay antihypertensive in dogs, often alongside RAAS blockade when both hypertension and proteinuria are present. Symptomatic and supportive care rounds out management: the antiemetic maropitant, acid suppression such as omeprazole when warranted, and the appetite stimulant capromorelin for dogs that are off their food; supplemental B-vitamins and omega-3 fatty acids; and, in advanced disease, subcutaneous fluids at home to support hydration and reduce uremic signs.

Monitoring, prognosis, and what to tell an owner

  • Recheck cadence: once therapeutic targets are met, re-evaluate dogs in Stages 2–4 roughly every three to four months — creatinine, SDMA, UPC, phosphorus, and blood pressure — to confirm targets are maintained and adjust binders and anti-proteinuric drugs.
  • Watch for acute decompensation: sudden anorexia, repeated vomiting, profound weakness, or collapse can signal a uremic crisis, and dogs in Stage 4 are at high risk; these are reasons for same-day care, sometimes with hospital fluids.
  • Prognosis by stage (median survival): Stage 1 > 400 days, Stage 2 200–400 days, Stage 3 110–200 days, Stage 4 14–80 days. Higher IRIS stage, persistent proteinuria, and uncontrolled hypertension shorten these numbers; early detection and tight phosphorus, UPC, and blood-pressure control extend them.

The honest framing for an owner is that canine CKD is a chronic, progressive disease managed over months to years. The workup's value is that it converts a vague "kidney failure" into a specific stage and substage with a defined plan — renal diet, phosphorus control, anti-proteinuric and antihypertensive therapy, and a recheck schedule — and an evidence-based expectation of how much good-quality time that plan is likely to buy.

Sources

Topics
Urology
Related Articles